MedTrace Logo

Lonafarnib in Metastatic Breast Cancer

NCT00773474 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2016-02-18

Study results available
· View outcomes & findings →

Summary

A published phase 2 study reported that lonafarnib was administered as a single agent via continuous or intermittent oral dosing to 76 women with advanced breast cancer who were previously treated with chemotherapy and/or with endocrine therapy. Objective response rates of approximately 10% were observed. This study will determine the rate of progression-free survival of patients with metastatic breast cancer who receive lonafarnib.

Conditions

Interventions

DRUG

Lonafarnib

All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Hoosier Cancer Research Network

    collaborator OTHER

  • George Sledge

    lead OTHER

Principal Investigators

  • George Sledge, M.D. · Hoosier Cancer Research Network

  • Brian Leland-Jones, M.D. · Hoosier Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00773474 on ClinicalTrials.gov